lloyd Carney Net Worth

The estimated Net Worth of Lloyd Carney is at least 37.4 百万$ dollars as of 26 April 2024. Mr. Carney owns over 909 units of Vertex Pharmaceuticals stock worth over 1,230,051$ and over the last 19 years he sold VRTX stock worth over 35,717,526$. In addition, he makes 494,534$ as Independent Director at Vertex Pharmaceuticals.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Carney VRTX stock SEC Form 4 insiders trading

lloyd has made over 36 trades of the Vertex Pharmaceuticals stock since 2007, according to the Form 4 filled with the SEC. Most recently he sold 909 units of VRTX stock worth 250,475$ on 26 April 2024.

The largest trade he's ever made was selling 1,050,916 units of Vertex Pharmaceuticals stock on 22 March 2017 worth over 13,104,923$. On average, lloyd trades about 73,386 units every 84 days since 2006. As of 26 April 2024 he still owns at least 2,591 units of Vertex Pharmaceuticals stock.

You can see the complete history of Mr. Carney stock trades at the bottom of the page.

lloyd Carney biography

Lloyd A. Carney is Independent Director of the Company. Mr. Carney is the Chairman and Chief Executive Officer of ChaSerg Technology Acquisition Corp., a technology acquisition company. He was the Chief Executive Officer of Brocade Communications Systems Inc., or Brocade, a global supplier of networking hardware and software, from January 2013 until 2017, when it was acquired by Broadcom. Prior to Brocade, he served as Chief Executive Officer of Xsigo Systems, a cloud-based infrastructure solutions provider, until its acquisition by Oracle. He has also served as the Chief Executive Officer and Chairman of Micromuse Inc., a software solutions provider for business and service assurance, until its acquisition by IBM. Earlier in his career he had held senior leadership roles at Juniper Networks, Inc., Nortel Networks Inc., and Bay Networks, Inc. He currently sits on the board of directors at Visa Inc. and Nuance Communications, Inc. He holds a Bachelor of Science degree in Electrical Engineering Technology from Wentworth Institute, a Master of Science degree in Applied Business Management from Lesley College, and an Honorary Doctorate degree in Engineering from Wentworth Institute.

What is the salary of lloyd Carney?

As the Independent Director of Vertex Pharmaceuticals, the total compensation of lloyd Carney at Vertex Pharmaceuticals is 494,534$. There are 20 executives at Vertex Pharmaceuticals getting paid more, with Jeffrey Leiden having the highest compensation of 18,790,000$.

How old is lloyd Carney?

lloyd Carney is 57, he's been the Independent Director of Vertex Pharmaceuticals since 2019. There are 7 older and 17 younger executives at Vertex Pharmaceuticals. The oldest executive at Vertex Pharmaceuticals, Inc. is William Young, 75, who is the Independent Director.

What's lloyd Carney's mailing address?

Lloyd's mailing address filed with the SEC is C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON, MA, 02210.

Insiders trading at Vertex Pharmaceuticals

Over the last 21 years, insiders at Vertex Pharmaceuticals have traded over 934,925,905$ worth of Vertex Pharmaceuticals stock and bought 308,652 units worth 12,298,449$ . The most active insiders traders include Lloyd Carney、Jeffrey M Leiden、Joshua S Boger. On average, Vertex Pharmaceuticals executives and independent directors trade stock every 5 days with the average trade being worth of 4,747,875$. The most recent stock trade was executed by Jeffrey M Leiden on 30 August 2024, trading 3,784 units of VRTX stock currently worth 1,888,216$.

What does Vertex Pharmaceuticals do?

Vertex Pharmaceuticals is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry.

Complete history of Mr. Carney stock trades at Nuance Communications Inc、Vertex Pharmaceuticals、Visa Inc、Grid Dynamics

Vertex Pharmaceuticals executives and stock owners

Vertex Pharmaceuticals executives and other stock owners filed with the SEC include:

• Jeffrey Leiden,
  Executive Chairman of the Board
• Stuart Arbuckle,
  Executive Vice President, Chief Commercial Officer
• Reshma Kewalramani,
  President, Chief Executive Officer, Director
• Amit Sachdev,
  Executive Vice President, Chief Regulatory Officer and Chief of Staff to the CEO
• David Altshuler,
  Executive Vice President - Global Research, Chief Scientific Officer
• Michael Parini,
  Executive Vice President, Chief Legal and Administrative Officer
• Dr. Reshma Kewalramani FASN, M.D.,
  CEO, Pres & Director
• Charles Wagner,
  Chief Financial Officer, Executive Vice President
• Paul Silva,
  Senior Vice President, Controller
• Dr. Jeffrey Marc Leiden M.D., Ph.D.,
  Exec. Chairman
• Stuart A. Arbuckle B.Sc.,
  Exec. VP & COO
• Dr. David M. Altshuler,
  Exec. VP of Global Research & Chief Scientific Officer
• Charles F. Wagner Jr.,
  Exec. VP & CFO
• Bruce Sachs,
  Co-Lead Independent Director
• Margaret McGlynn,
  Independent Director
• Terrence Kearney,
  Independent Director
• Sangeeta Bhatia,
  Independent Director
• Yuchun Lee,
  Independent Director
• William Young,
  Independent Director
• Alan Garber,
  Independent Director
• lloyd Carney,
  Independent Director
• Michael Partridge,
  Vice President - Investor Relations
• Diana McKenzie,
  Independent Director
• Nia Tatsis,
  Senior Vice President, Chief Regulatory Officer
• John Gray,
  Senior Vice President, Genetic Therapies
• Gerald Bruce,
  Executive Vice President, Commercial Operations
• Carmen Bozic,
  Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
• Joy Liu,
  Sr. VP & Gen. Counsel
• Damian W. Wilmot Esq.,
  Sr. VP, Chief Risk and Compliance Officer
• Mike Tirozzi,
  SVP and Chief Information & Data Officer
• Kristen Ambrose,
  Chief Accounting Officer & SVP of Accounting, Tax, Treasury, Strategic Sourcing & Corp. Services
• Joshua S Boger,
  Chairman & CEO
• Elaine Ullian,
  Director
• Ian F Smith,
  SVP & CFO
• Jeffrey Chodakewitz,
  SVP GMDA, CMO
• Thomas Graney,
  Chief Financial Officer
• Michel Lagarde,
  Director
• Wayne Joseph Riley,
  Director
• Peter Mueller,
  CSO & SVP Drug Discovery
• Thomas Connolly,
  SVP, Human Resources
• Kenneth L Horton,
  EVP & Chief Legal Officer
• Megan E Pace,
  SVP, Corp. Communications
• Christiana Stamoulis,
  SVP, Corp Strategy & Bus Devlp
• Matthew Emmens,
  Director
• Lisa Kelly,
  SVP, Human Resources
• Dennis L Winger,
  Director
• Eugene Cordes,
  Director
• Nancy Wysenski,
  EVP & Chief Commercial Officer
• David T Howton,
  SVP
• Kenneth S Boger,
  SVP & General Counsel
• Kurt Graves,
  EVP, Chief Commercial Officer
• John J Alam,
  SVP, Drug Eval. & Appr.
• Stuart J Collinson,
  Director
• Charles A Sanders,
  Director
• Roger W Brimblecombe,
  Director
• Freda C Lewis Hall,
  EVP, Medicines Development
• Eve Elizabeth Slater,
  Director
• Richard C Garrison,
  SVP, Organizational Developmen
• Johanna Messina Power,
  Controller
• Victor A Hartmann,
  EVP, Strategic & Corp. Devlp.
• Eric Brandt,
  Director
• Lynne H Brum,
  VP, Corp. Comm.&Financial Plan
• Paul A Negulescu,
  VP, Research
• John F Niblack,
  Director
• Iain P M Buchanan,
  VP, European Operations
• Vicki L Sato,
  President
• N Anthony Coles,
  SVP, Comm. Ops.
• Bastiano Sanna,
  EVP, Cell & Genetic Therapies
• Joy Liu,
  SVP, General Counsel
• Kristen Ambrose,
  SVP & Chief Accounting Officer
• Suketu Upadhyay,
  Director
• Jonathan Biller,
  EVP and Chief Legal Officer
• Nancy Thornberry,
  Director
• Edward Morrow Iii Atkinson,
  EVP, Chief Technical Ops. Off.
• Jennifer Schneider,
  Director